319 related articles for article (PubMed ID: 38612471)
1. A Review of FDA-Approved Anti-HIV-1 Drugs, Anti-Gag Compounds, and Potential Strategies for HIV-1 Eradication.
Sever B; Otsuka M; Fujita M; Ciftci H
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612471
[TBL] [Abstract][Full Text] [Related]
2. Bcl-2 Antagonist Obatoclax Reactivates Latent HIV-1 via the NF-κB Pathway and Induces Latent Reservoir Cell Apoptosis in Latently Infected Cells.
Zhou C; Li T; Xia M; Wu Z; Zhong X; Li A; Rashid HK; Ma C; Zhou R; Duan H; Zhang X; Peng J; Li L
ACS Infect Dis; 2023 Nov; 9(11):2105-2118. PubMed ID: 37796279
[TBL] [Abstract][Full Text] [Related]
3. Screening of an FDA-approved compound library identifies levosimendan as a novel anti-HIV-1 agent that inhibits viral transcription.
Hayashi T; Jean M; Huang H; Simpson S; Santoso NG; Zhu J
Antiviral Res; 2017 Oct; 146():76-85. PubMed ID: 28842263
[TBL] [Abstract][Full Text] [Related]
4. HIV Reservoirs and Treatment Strategies toward Curing HIV Infection.
Matsuda K; Maeda K
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473868
[TBL] [Abstract][Full Text] [Related]
5. Strategies in the Design and Development of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs).
Vanangamudi M; Palaniappan S; Kathiravan MK; Namasivayam V
Viruses; 2023 Sep; 15(10):. PubMed ID: 37896769
[TBL] [Abstract][Full Text] [Related]
6. Lenacapavir: A Novel, Potent, and Selective First-in-Class Inhibitor of HIV-1 Capsid Function Exhibits Optimal Pharmacokinetic Properties for a Long-Acting Injectable Antiretroviral Agent.
Subramanian R; Tang J; Zheng J; Lu B; Wang K; Yant SR; Stepan GJ; Mulato A; Yu H; Schroeder S; Shaik N; Singh R; Wolckenhauer S; Chester A; Tse WC; Chiu A; Rhee M; Cihlar T; Rowe W; Smith BJ
Mol Pharm; 2023 Dec; 20(12):6213-6225. PubMed ID: 37917742
[TBL] [Abstract][Full Text] [Related]
7. Biktarvy for the treatment of HIV infection: Progress and prospects.
De Clercq E; Zhang Z; Huang J; Zhang M; Li G
Biochem Pharmacol; 2023 Nov; 217():115862. PubMed ID: 37858869
[TBL] [Abstract][Full Text] [Related]
8. Lenacapavir: A novel injectable HIV-1 capsid inhibitor.
Hitchcock AM; Kufel WD; Dwyer KAM; Sidman EF
Int J Antimicrob Agents; 2024 Jan; 63(1):107009. PubMed ID: 37844807
[TBL] [Abstract][Full Text] [Related]
9. Current ARTs, Virologic Failure, and Implications for AIDS Management: A Systematic Review.
Foka FET; Mufhandu HT
Viruses; 2023 Aug; 15(8):. PubMed ID: 37632074
[TBL] [Abstract][Full Text] [Related]
10. HIV infection.
Bekker LG; Beyrer C; Mgodi N; Lewin SR; Delany-Moretlwe S; Taiwo B; Masters MC; Lazarus JV
Nat Rev Dis Primers; 2023 Aug; 9(1):42. PubMed ID: 37591865
[TBL] [Abstract][Full Text] [Related]
11. Targeting and eradicating latent CNS reservoirs of HIV-1: Original strategies and new models.
Saeb S; Wallet C; Rohr O; Schwartz C; Loustau T
Biochem Pharmacol; 2023 Aug; 214():115679. PubMed ID: 37399950
[TBL] [Abstract][Full Text] [Related]
12. Long-acting lenacapavir acts as an effective preexposure prophylaxis in a rectal SHIV challenge macaque model.
Bekerman E; Yant SR; VanderVeen L; Hansen D; Lu B; Rowe W; Wang K; Callebaut C
J Clin Invest; 2023 Aug; 133(16):. PubMed ID: 37384413
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
